This preprint has been removed

Abstract

Background Current COVID-19 treatment methods are in the form of oral tablets or intravenous therapy. However, even if the efficacy of these agents is shown in in-vitro studies, the same effect cannot be seen in in-vivo. This is because these treatments are intended to reach the lungs through the blood. However, severe interstitial edema and blood alveolar barrier does not allow medications to reach the lungs effectively. Objective In the new inhaler treatment (NIT) given in this clinical study, the molecules that have antiviral, antioxidant and anti-inflammatory effects without any toxicity were brought together. This study aims to prevent rapid and effective clinical improvement in COVID-19 patients and prevent any complications related to COVID-19 infection. Methods This study approved by The Ministry of Health of Turkey. This clinical study was designed as a multi-center study and performed in Istanbul and Mersin, Turkey. The patients were divided into two groups. Patients were randomly assigned following simple randomization procedures. Eight patients received the normal treatment protocol, while eight patients received the new inhalation treatment protocol in addition to the normal treatment protocol. It was applied by connecting the T nebulizer device in intubated patients and with a nebulizer mask in non-intubated patients. Pulse oxygen saturation, respiratory rate, percentage of lung involvement, arterial blood gas, and duration of hospitalization were compared after the treatment. Results One of the most important points of this study is the duration of hospital stay between the two groups. The mean duration of hospitalization in group 1 was 6.5 ± 1.8; in group 2 it was 17.1 ± 2.4. The duration of stay in Group 1 was significantly lower than group 2. (P < 0.05) FOS (Finger oxygen saturation) values were 89.2 ± 4.8 and 96.1 ± 4.7 in group 1 at the end of the 3rd and 7th days, respectively. In group 2, it was 80.3 ± 5.9 and 84.6 ± 4.4. After treatment FOS levels were significantly higher in group 1 for days 3 and 7. (P < 0.05) Conclusion Methods of treatment with multiple molecules should be developed for complex diseases, not single molecule therapy. In this sense, this study is very important as it will bring a new perspective to the scientific world. With the treatment mentioned in the current study; It is important in terms of making a new prophylaxis and therapeutic plan for Covid-19. It is thought that it will be unique in terms of creating a treatment plan with low potential for natural and non-synthetic side effects instead of using toxic and side effects products.